Negative in Ames, in vitro CHO chromosomal aberration, in vivo rat micronucleus and rat unscheduled DNA synthesis assays
“Bexagliflozin was not mutagenic or clastogenic with or without metabolic activation in the in vitro Ames bacterial mutagenicity assay, the in vitro CHO cell assay, an in vivo micronucleus assay in rats, and an in vivo unscheduled hepatic DNA synthesis study in rats.”
2-year SD rat and CD-1 mouse: no neoplastic findings (about 54x and 135x clinical AUC)
“The carcinogenic potential of bexagliflozin was evaluated in 2-year studies in Sprague-Dawley (SD) rats and CD-1 mice. There were no neoplastic findings in mice and rats up to the highest doses tested (150 mg/kg/day for mice and 30 mg/kg/day for rats, representing approximately 135 and 54 times the clinical dose of 20 mg based on AUC, respectively).”
No adverse effects on rat fertility, rat or rabbit embryofetal development, or rat pre/postnatal development
“Bexagliflozin produced no adverse effects on fertility in rats, on embryofetal toxicity in rats or rabbits, or on pre- and postnatal development in rats at clinically relevant exposures.”
“Bexagliflozin did not affect hERG channel-mediated potassium current in HEK293 cells up to the maximum tested concentration of 25 mcM (17,380 ng/mL, 99-fold MRHD based on clinical Cmax of 176 ng/ml)”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative